Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-25-084313
Filing Date
2025-04-17
Accepted
2025-04-17 16:05:42
Documents
11
Period of Report
2025-05-28

Document Format Files

Seq Description Document Type Size
1 DEF 14A d884353ddef14a.htm DEF 14A 401960
2 GRAPHIC g884353dsp01.jpg GRAPHIC 10534
3 GRAPHIC g884353dsp01a.jpg GRAPHIC 91344
4 GRAPHIC g884353dsp01b.jpg GRAPHIC 4073
5 GRAPHIC g884353dsp01c.jpg GRAPHIC 3408
6 GRAPHIC g884353dsp01d.jpg GRAPHIC 3834
7 GRAPHIC g884353dsp01e.jpg GRAPHIC 4212
8 GRAPHIC g884353dsp02.jpg GRAPHIC 1237
9 GRAPHIC g884353dsp02a.jpg GRAPHIC 1422
10 GRAPHIC g884353g06s06.jpg GRAPHIC 24008
11 GRAPHIC g884353g11l28.jpg GRAPHIC 48746
  Complete submission text file 0001193125-25-084313.txt   667144
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

EIN.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40656 | Film No.: 25847292
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)